PARABILIS MEDIC.INC. O.N.

Parabilis Medicines has appointed Dr. Craig L. Tendler, the former global head of late clinical development and medical affairs in oncology at J&J, to its board of directors. Tendler brings more than 30 years of experience in oncology drug development and was involved in over 30 regulatory approvals and 13 FDA breakthrough therapy designations. He will remain a scientific advisor to Parabilis and currently serves on other boards as well as acting as the alternate industry representative on the FDA Oncologic Drugs Advisory Committee. Parabilis is developing the clinical candidate zolucatetide for multiple solid tumor indications. » Más en de.investing.com

Director Alan Sebulsky purchased 17,500 Parabilis Medicines shares in open-market trades on June 12 and June 15 for about $474,000, at a weighted average price of $27.06 per share executed through Apothecary Capital LLC. The purchase increased his indirect holdings to 30,000 shares while his direct holdings remain zero; he previously acquired 12,500 IPO shares at $20 and holds granted stock options. The open-market buy at a price above the recent close is presented as a bullish insider signal shortly after the company's June 10 IPO. » Más en finance.yahoo.com